Synthetic MVA Coronavirus Vaccine Platform for Vector Availability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for coronaviruses, such as SARS-CoV-2, are limited by the restricted availability of Modified Vaccinia Ankara (MVA) vectors, which are largely controlled by academic, commercial, or governmental entities, and there is a need for vaccines that can provide long-term and cross-reactive immunity against emerging variants.
Innovation Solution
A synthetic MVA platform is developed, incorporating DNA fragments of the MVA genome and codon-optimized human coronavirus antigens, such as Spike and Nucleocapsid proteins, to create a vaccine composition that can be expressed in host cells, including stabilized prefusion forms of the S protein and N protein, to enhance immunogenicity and cross-reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MVA vectors are used for coronavirus vaccine development, then safety and immunogenicity are improved, but availability and accessibility are worsened due to restricted control by academic, commercial, or governmental entities
Solution Approach 1:
The patent creates a synthetic MVA platform that copies the essential features of authentic MVA virus (safety profile, immunogenicity) while using chemically synthesized DNA fragments instead of relying on traditional MVA vector propagation. This synthetic approach enables independent production outside the restricted MVA vector supply chain controlled by academic, commercial, or governmental entities.
Solution Approach 2:
The invention extracts only the necessary genomic elements from MVA (DNA fragments encoding viral proteins) and combines them with coronavirus antigen genes in a synthetic construction system. This extraction allows creation of functional vaccine vectors without requiring access to complete, authentic MVA virus stocks held by restricted entities.
2Adaptability or versatility
If traditional MVA vectors are used, then vaccine development is constrained by limited availability, but using alternative platforms may reduce immunogenicity or safety
Solution Approach 1:
The patent optimizes DNA sequences through codon optimization for mammalian expression systems, enhancing antigen production efficiency. The synthetic DNA fragments are designed with optimized coding sequences, regulatory elements, and structural features that maximize immunogenicity while maintaining the safety profile associated with MVA-based platforms.
Solution Approach 2:
The synthetic platform copies the successful immunogenicity features of authentic MVA vectors by incorporating MVA DNA fragments that encode viral proteins essential for immune stimulation, while replacing the need for proprietary MVA virus stocks with synthetically constructed DNA-based vectors that can be produced independently.
3Ease of manufacture
If DNA fragments are assembled in host cells upon co-transfection, then vaccine production flexibility is improved, but manufacturing complexity increases
Solution Approach 1:
The MVA genome is divided into multiple synthetic DNA fragments that can be independently synthesized, validated, and assembled. This segmentation allows flexible production where fragments can be manufactured separately and then assembled in host cells through co-transfection, enabling modular vaccine development and production scaling.
Solution Approach 2:
Host cells serve as intermediary systems that facilitate the assembly of synthetic DNA fragments into functional vaccine vectors. The co-transfection process uses host cell machinery to assemble the DNA fragments and express the encoded antigens, providing a biological intermediary that simplifies the manufacturing process compared to direct chemical assembly.
Data Source
AI summary
Synthetic MVA-based vaccine compositions for preventing or treating a virus infection such as a coronavirus infection and methods of producing the vaccines. The vaccine compositions include (i) either a single DNA fragment that includes the entire genome of MVA, or two or more DNA fragments, each including a partial sequence of the genome of the MVA such that the two or more DNA fragments, when expressed in the host cell upon co-transfection, are assembled sequentially and comprise the full-length sequence of the MVA genome, and (ii) one or more DNA sequences encoding one or more human coronavirus antigens, subunits, or fragments thereof inserted in one or more insertion sites of the MVA. The antigens, subunits, or fragments thereof are expressed in the host cell upon transfection of the one or more DNA fragments.